Market Intelligence, Clinical Progress, and High-Purity Reagents for Chronic Inflammatory Diseases and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAPK13 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAPK13 Active / Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified by Mass Spec. Suitable for kinase profiling. |
View MAPK13 Products |
| Gene Delivery | MAPK13 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and target engagement assays. |
View MAPK13 Products |
| Benchmark Ab | Anti-MAPK13 Recombinant Antibody High-specificity positive control for Western Blot and ELISA validation. |
View MAPK13 Products |
| Validator | MAPK13 siRNA Set Target-specific knockdown verification to confirm phenotype specificity. |
View MAPK13 Products |
| Related Target A | MAPK14 (p38 alpha) Essential for counter-screening to ensure isoform-selective inhibition. |
View MAPK14 Products |
| Related Target B | MAPK12 (p38 gamma) Close homolog used to evaluate off-target profile within the p38 family. |
View MAPK12 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High Sequence Homology among p38 isoforms (alpha, beta, gamma, delta) | Full panel of recombinant p38 family proteins (MAPK11, MAPK12, MAPK13, MAPK14) with sequence-verified purity >95%. |
| Assaying intracellular kinase target engagement | High-titer Lentivirus Premade Particles for robust expression in target disease cell lines. |
| Lack of highly specific control antibodies | Sequence-defined recombinant monoclonal antibodies targeting unique MAPK13 C-terminal epitopes. |
| Off-target kinase toxicity screening | Pre-validated target-specific siRNA sets for loss-of-function control experiments. |
Live MAPK13/SAPK4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of MAPK13 (p38 delta) is gaining traction as researchers seek to overcome the systemic toxicity associated with broad p38 MAPK inhibitors. While early-generation p38 inhibitors primarily targeted MAPK14 (p38 alpha) and suffered from dose-limiting toxicities in inflammatory diseases, MAPK13-specific modulation offers a safer, more tissue-restricted therapeutic window. Current R&D is shifting focus from pan-p38 inhibitors to highly selective small molecule inhibitors and PROTACs targeting MAPK13 in squamous cell carcinoma, rheumatoid arthritis, and neurodegenerative diseases such as Alzheimer's, where MAPK13 drives tau hyperphosphorylation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic/Biotech Consortia | Squamous Cell Carcinoma, COPD | Kinase Selectivity Assays (Requires high-purity MAPK11/12/13/14 proteins) |
| PROTACs / Degraders | Targeted Protein Degradation Pioneers | Neurodegenerative Diseases | Target Engagement & Degradation Kinetics (Requires Lentivirus for stable cell line assays) |
| siRNA Therapeutics | RNAi Developers | Inflammatory Skin Disorders | In vitro knockdown validation (Requires validated siRNA controls) |